All News

The Executive Guide to Contracts & Chargebacks Management - CDC PE Whitepaper

06 August 2009

21 August 2009

Inside Outsourcing 2009

18 August 2009

04 August 2009

3 August 2009

Dietary supplements function like drugs and are marketed like drugs. They should be regulated like ducks.

Through innovative patient compliance programs, manufacturers are taking steps to meet the needs of patients and the pharma industry.

30 July 2009

The drug giant, last week, started tweeting about corporate initiatives, job openings, and news. Is Pfizer just jumping on the bandwagon, or is Twitter part of the company's social media strategy? Pharm Exec talks to Pfizer to find out more.

Trial participants being treated for pulmonary hypertension suffered sickle cell pain in clinical trial. The cause: the active ingredient in Viagra.

With thousands of UPLC systems and UPLC columns delivered worldwide, see why the world's top-branded companies and institutions have standardized on ACQUITY UPLC: the fastest-growing new LC platform in the market for five years running.

Collins seeks to parlay genomic discoveries into new biomedical therapies. Comparative effectiveness research, he says, should identify subpopulation responses to treatment and support personalized medicine.

Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.

The process of research and development of new drugs has become phenomenally expensive. Can Lean Six Sigma revitalize the innovation process for pharmaceutical companies?

20 July 2009

Pain medications containing propoxyphene could lead to overdose and death, according to new labeling mandated by FDA. However, public requests to take these drugs (including Darvon and Darvocet) off the market have been denied.

08 July 2009

Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it.

Biopharmaceutical companies generally try to avoid paying royalties on novel technologies, including novel expression systems, in part because of the inability to predict revenue flow after a product is commercialized. But even when a new expression system could significantly reduce cost, many remain hesitant. Despite this, adopting new technologies continues to be fundamental to improving product quality and cost.

In the long run, pharma wants to sell health, not just drugs.

As FDA looks to balance risks and benefits, more regulations are on the horizon.

Increasingly, pharma companies are expanding from brand vs. brand to battle at the franchise, portfolio, and corporate levels.

June TOC

Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition.